Leerink Partners Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock

Belite Bio (NASDAQ:BLTE) had its target price increased by equities researchers at Leerink Partners from $185.00 to $215.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners‘s price objective would indicate a potential upside of 28.95% from the company’s current price.

BLTE has been the topic of several other reports. Canaccord Genuity Group assumed coverage on Belite Bio in a research report on Friday, September 4th. They set a “buy” rating and a $303.00 price objective on the stock. Benchmark reiterated a “buy” rating on shares of Belite Bio in a research note on Friday, August 14th. Cantor Fitzgerald boosted their price objective on shares of Belite Bio from $266.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. HC Wainwright restated a “buy” rating and set a $245.00 price objective on shares of Belite Bio in a research report on Thursday, October 15th. Finally, Zacks Research cut shares of Belite Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 18th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Belite Bio currently has an average rating of “Moderate Buy” and an average target price of $226.27.

Belite Bio Stock Down 1.9%

Shares of NASDAQ BLTE traded down $3.23 during midday trading on Friday, hitting $166.73. The stock had a trading volume of 181,270 shares, compared to its average volume of 190,771. The business’s 50 day moving average is $161.02 and its 200-day moving average is $160.25. The company has a market cap of $6.71 billion, a P/E ratio of -61.07 and a beta of -1.19. Belite Bio has a 52 week low of $105.88 and a 52 week high of $200.00.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.19. As a group, analysts expect that Belite Bio will post -3.08 EPS for the current fiscal year.

Insider Transactions at Belite Bio

In related news, CEO Yu-Hsin Lin sold 74,435 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $187.71, for a total value of $13,972,193.85. Following the transaction, the chief executive officer directly owned 96,134 shares of the company’s stock, valued at approximately $18,045,313.14. This trade represents a 43.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Hendrik Scholl sold 500 shares of Belite Bio stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $165.32, for a total value of $82,660.00. Following the transaction, the insider owned 14,500 shares in the company, valued at $2,397,140. This trade represents a 3.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 168,330 shares of company stock worth $31,969,118 in the last 90 days. 13.29% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. State Street Corp lifted its position in shares of Belite Bio by 6.9% in the third quarter. State Street Corp now owns 34,044 shares of the company’s stock worth $5,781,000 after buying an additional 2,196 shares in the last quarter. Alberta Investment Management Corp purchased a new position in Belite Bio during the 3rd quarter valued at approximately $4,076,000. Candriam S.C.A. purchased a new position in Belite Bio during the 3rd quarter valued at approximately $10,711,000. Vise Technologies Inc. bought a new stake in Belite Bio in the 3rd quarter worth approximately $217,000. Finally, GAMMA Investing LLC increased its stake in Belite Bio by 5.0% in the 3rd quarter. GAMMA Investing LLC now owns 1,771 shares of the company’s stock worth $301,000 after acquiring an additional 85 shares during the last quarter. Institutional investors own 0.53% of the company’s stock.

Recent Belite Bio Headlines

Here are a few of the latest headlines about BLTE:

• Positive Sentiment: The FDA accepted Belite Bio’s tinlarebant NDA for priority review, moving the drug closer to a potential first-ever treatment for Stargardt disease. This regulatory milestone may support investor optimism as the FDA review proceeds. Belite Bio Q3 2026 Earnings Call Highlights
• Positive Sentiment: BLTE reported a third-quarter loss of $0.60 per share, narrower than analysts’ expected $0.79 loss. The earnings beat offers a favorable near-term signal, though it does not change the company’s development-stage profile. Belite Bio quarterly earnings results
• Negative Sentiment: Belite Bio reported a $30.3 million quarterly net loss. The loss underscores the costs and uncertainty involved in advancing its drug pipeline; the company has not yet established a commercial revenue base. Belite Bio reveals quarterly loss

About Belite Bio

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.